Press Release — New Blog — Verge Genomics

Posts in Press Release

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Press ReleaseRob MaguireMarch 25, 2024

Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference

Press ReleaseRob MaguireFebruary 21, 2024

Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635

Press ReleaseRob MaguireJanuary 9, 2024

Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

Press ReleaseRob MaguireJanuary 3, 2024

Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635

Press ReleaseRob MaguireNovember 29, 2023

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration

Press ReleaseRob MaguireOctober 31, 2023

Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases

Press ReleaseRob MaguireSeptember 8, 2023

Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

Press ReleaseRob MaguireJune 15, 2023

Verge Genomics to Present at Mass General Brigham & Bank of America World Medical Innovation Forum

Press ReleaseRob MaguireJune 6, 2023

Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial

Press ReleaseRob MaguireMay 23, 2023

Verge Genomics to Present at 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023

Press ReleaseRob MaguireJanuary 4, 2023

Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer

Press ReleaseRob MaguireDecember 6, 2022

VERGE GENOMICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN NOVEMBER

Press ReleaseRob MaguireNovember 21, 2022

Alice Zhang, CEO & Co-founder of Verge Genomics, Recognized Today by Both Fortune and Fierce Biotech as a Pioneer in AI-Driven Drug Discovery

Press ReleaseRob MaguireNovember 14, 2022

Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, A Novel Therapeutic for Amyotrophic Lateral Sclerosis

Press ReleaseRob MaguireOctober 31, 2022

Verge Genomics Appoints John Applegate as Chief Financial Officer

Press ReleaseRob MaguireOctober 17, 2022

Verge Genomics Honored by Goldman Sachs for Entrepreneurship

Press ReleaseRob MaguireOctober 12, 2022

Fierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company

Fierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company

Press ReleaseRob MaguireSeptember 12, 2022

Alfred W. Sandrock, Jr., M.D., Ph.D., Joins Verge Genomics’ Board of Directors

Press ReleaseRob MaguireFebruary 8, 2022

Verge Genomics to Present at 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Press ReleaseRob MaguireJanuary 6, 2022